Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Cancer Res. 2017 Jul 5;23(19):5836–5845. doi: 10.1158/1078-0432.CCR-16-2862

Figure 3.

Figure 3

IC50 dose response curves of SYD985, T-DM1 and ADC isotype control in all CS cell lines tested in vitro [i.e., HER2 3+ cell lines (SARARK-6 and SARARK-9), p = <0.0001 and HER2 1+/0 cell lines (SARARK-1 and SARARK-7), p = <0.0001] at 3 days. SARARK-6 and SARARK-7 are ovarian in origin. SARARK-1 and SARARK-9 are uterine in origin.